药明康德本月股价涨幅已达41.90%。在昨日发布营收、净利均同比双位数增长的半年报后，今日药明 康德A股上涨7.72%，报收98.69元/股；H股上涨11.25%，报收111.70港元/股。 面对每天上千份上市公司公告该看哪些？重大事项公告动辄几十页几百页重点是啥？公告里 一堆专业术语不知道算利好还是利空？请看智通财经公司新闻部《速读公告》栏目，我们派 驻全国的记者们将于公告当晚为您带来准确、快速、专业的解读。 智通财经7月29日讯（记者 武超 卢阿峰）近阶段，医药板块持续升温，频频释放利好的药明康德 （603259.SH）股价也持续攀升，现已恢复至3年前的位置。而公司今晚一则"调高回购股份价格上限"的 公告，则进一步显露出对未来的信心。 据公告，药明康德拟将2025年第一次以集中竞价交易方式回购A股股份的回购股份价格上限由不超过 90.72元/股（含）调整为不超过114.15元/股，即不高于董事会通过本次决议前30个交易日公司股票交易 均价的150%。 此前，药明康德审议通过《关于2025年以集中竞价交易方式回购公司A股股份的议案》，同意公司以总 额为10亿元的自有资金和自筹资金、以集中竞价交易方式回购公司 ...

药明康德还宣布中期分红方案，共计约为10亿元，拟每10股派发现金红利3.5元。2025年以来，公司现 金分红与回购注销规模达到近70亿元。 新京报贝壳财经讯 药明康德（603259）发布2025年半年报，报告期内，公司实现营业收入207.99亿元， 同比增长20.64%；归属于上市公司股东的净利润85.6亿元，同比增长101.92%。 ...

把握中国龙头药企价值重估机遇，配置工具关注国内首只药ETF（562050）。聚焦A股50大龙头药企， 重仓创新药，兼顾高壁垒仿制药及中药，且完全不含医疗和CXO。 分析人士指出，药明康德上半年营业收入、净利润均创下历史新高，第二季度单季营收首次站上百亿元 台阶，达到111.45亿元。作为CXO"一哥"，逆势交出"最强"中报，向市场注入"强心剂"，并印证行业或 正加速回暖。 中金公司指出，如今创新药板块估值中枢上修，预期BD资金和二级热度上涨将反哺国内新药研发需求 起量以及一级创新药项目融资活跃度提升，内需CRO有望受益。另一方面，中国企业成本与效率优势 对海外客户具较强吸引力，外需CDMO订单趋势同样向好。 药明康德交出"史上最强"半年报，CXO板块沸腾！医疗ETF（512170）覆盖的6只CXO龙头股集体上 攻，药明康德涨7.72%，股价逼近100元，创3年新高！成交90.14亿元，位列A股第7。此外，九洲药业 涨停，昭衍新药午后触板。 中泰证券提示，随着财报陆续披露，CXO、GLP-1等景气赛道表现亮眼。后续建议继续重点关注有望逐 步走出拐点的细分板块，如CXO、科研上游等。 把握CXO、医疗器械拐点向上 ...

今年以来，创新药迎来一波火热行情，赋能医药研发与生产的医药外包企业也出现回暖迹象。7月29日，医药外包龙头企业药明康德 （603259）交出了一份史上最强中报。 药明康德2025年半年度报告显示，公司上半年实现营业收入约为207.99亿元，同比增长20.64%；对应实现的归属净利润约为85.61亿 元，同比增长101.92%；扣非净利润约为55.82亿元，同比增长26.47%。公司营收、净利均创下历史新高。 | | | | 早刊: 九 川州: 八尺川 | | --- | --- | --- | --- | | 主要会计数据 | 本报告期 | 上年同期 | 本报告期比上 | | | (1-6月) | | 年同期增减(%) | | 营业收入 | 20,799,281,882.46 | 17,240,918,263.02 | 20.64 | | 利润总额 | 9.907.416.557.97 | 5.049.553.770.35 | 96.20 | | 归属于上市公司股东的净利润 | 8.560.882.627.56 | 4.239.822.013.11 | 101.92 | | 归属于上市公司股东的扣除非经常 | ...

Group 1 - WuXi AppTec plans to adjust the maximum repurchase price of its A-shares from 90.72 yuan to 114.15 yuan per share, while the other details of the repurchase plan remain unchanged. The current closing price is 98.69 yuan per share [1] Group 2 - Time Space Technology has terminated the planning of a change in control due to the inability to reach an agreement on core terms with its controlling shareholder. The termination will not have a significant adverse impact on the company's operating performance and financial status [2] Group 3 - Dong'an Power's indirect controlling shareholder has changed to China Changan Automobile following the division of the Equipment Group approved by the State Council. China Changan now indirectly holds 50.93% of Dong'an Power's total shares [3] Group 4 - Changchun High-tech's subsidiary has received FDA approval for its innovative drug, Amlodipine Besylate Oral Solution Lyophilized Powder, aimed at treating hypertension in children over 6 years old and adults with swallowing difficulties [4] Group 5 - Wantong Intelligent Control has signed an exclusive authorization agreement with Shanghai Shenming Aosi Semiconductor Technology for the production and sale of boards based on the Fellow 1 model chip in the embodied intelligence field, which is expected to positively impact the company's future development [5] Group 6 - Hunan Tianyan's indirect controlling shareholder has changed to China Changan Automobile after the division of the Equipment Group. China Changan now indirectly holds 37.25% of Hunan Tianyan's shares [6] Group 7 - Zhixiang Jintai has received approval for clinical trials of its product, Silevimi Monoclonal Antibody Injection, aimed at passive immunity for suspected rabies virus exposure in children and adolescents [7] Group 8 - Liyuan Technology's actual controller has been sentenced to one year in prison for the crime of disclosing important information in violation of regulations, but this will not significantly impact the company's operations [8] Group 9 - Huqin Technology plans to acquire 6% of Crystal Integrated's shares for 2.393 billion yuan, with the aim of deepening resource integration and strategic investment [10] Group 10 - Lakala's major shareholder, Lenovo Holdings, has reduced its stake by 5.3596 million shares, bringing its ownership down to 25.86%, which will not affect the company's governance structure [11]

药明康德(603259.SH)公告称，公司预计2025年持续经营业务收入重回双位数增长，增速从10-15%上调 至13-17%。公司预计全年整体收入从人民币415-430亿元上调至人民币425-435亿元。公司将持续聚焦 CRDMO核心业务，持续提高生产经营效率。2025年上半年，为加大股东回报，公司首次进行特别分红 约人民币10亿元（该分红已于2025年5月完成）；同时，为进一步提高分红频次，增强投资者回报水平 和获得感，公司董事会已审批通过《关于公司2025年中期利润分配方案的议案》，拟共计派发现金红利 约人民币10亿元。 ...

海外业务的高韧性成为业绩增长的重要驱动力。今年上半年，公司持续经营收入204.1亿元，海外客户 收入占比约85%。其中，来自美国客户的收入有140.3亿元，同比增长38.4%；来自欧洲客户的收入有 23.3亿元，同比增长9.2%。 信达证券研报指出，从2024年生物安全法案到2025年中美关税冲突，市场对于地缘政治风险的担忧已经 充分演绎，2025年H1公司来自美国客户的业务增速依然强劲，再次打消市场疑虑，全球化趋势难以抵 挡，公司在全球产业链中地位稳健。 细分业务中，TIDES（寡核苷酸和多肽）表现尤为亮眼。上半年，药明康德TIDES业务保持高速增长， 成为拉动业绩的关键因素之一。其业务收入50.3亿元，同比增长1.42倍，约占公司整体收入的24%。 7月29日，药明康德港股涨超11%，带动今日港股CRO板块逆势走强，泰格医药涨超9%，昭衍新药涨超 9%，康龙化成涨超7%。板块集体上扬的背后，是药明康德前一日发布的半年报数据为市场注入强心 针。 前一日晚间，药明康德公布2025年半年报。药明康德上半年营业收入208亿元，同比增长20.6%。归母 净利润85.61亿元，同比增长101.9%。今年上半年，公司持 ...

Core Viewpoint - WuXi AppTec (2359.HK) reported better-than-expected performance in the first half of the year, with revenue reaching 20.8 billion yuan, a year-on-year increase of 20.6% [1] - Net profit increased by 102% year-on-year to 8.6 billion yuan, while recurring net profit, excluding a one-time gain of 3.3 billion yuan from the sale of WuXi AppTec's stake, grew by 26.5% to 5.9 billion yuan [1] Financial Performance - Revenue for the first half of the year was 20.8 billion yuan, reflecting a 20.6% year-on-year growth [1] - Net profit surged by 102% year-on-year to 8.6 billion yuan [1] - Recurring net profit increased by 26.5% to 5.9 billion yuan when excluding one-time gains [1] Guidance and Projections - Management raised the full-year revenue guidance by 2% to a range of 42.5 billion to 43.5 billion yuan [1] - Free cash flow guidance was increased by 22% to a range of 5 billion to 6 billion yuan [1] - Capital expenditure budget remains unchanged at 7 billion to 8 billion yuan [1] Business Segments - TIDES business revenue grew by 142% year-on-year to 5 billion yuan, driven by GLP-1 raw material drugs, exceeding the annual growth target of 60% [1] - The second quarter gross margin reached a new high of 46.9%, attributed to improved production efficiency in the chemical business and an increase in later-stage projects [1] - However, only 8 new commercialization and phase III projects were added in the first half, and the China business experienced a year-on-year decline of 5% [1] Analyst Rating - The firm reiterated an outperform rating with a target price of 116 HKD [1]

药明康德（603259）(02359)公布，公司于2025年7月 29 日召开第三届董事会第二十三次会议，审议通 过了《关于调整回购股份价格上限的议案》，公司拟将 2025 年第一次以集中竞价交易方式回购A股股 份的回购股份价格上限由不超过 90.72 元/股(含)调整为不超过人民币 114.15 元/股，本次回购方案的其 他内容不变。 ...

医药医疗加快上行脚步！A股最大医疗ETF（512170）今日（2025年7月29日）刷新多项纪录：收涨2.45%报0.377元，收盘价创去年"924"以来次高！日线豪 取10连阳，刷新历史最长连阳纪录！全天成交11.52亿元，为近3个月次高。 制药板块同步活跃，国内首只药ETF（562050）盘中摸高2%，场内收涨1.68%，收盘价续创上市以来新高。百亿美元出海大单加持，核心权重股恒瑞医药继 昨日涨停后续涨2.84%，成交107.31亿元，跻身A股前三。 图片来源： 企业供图 药明康德交出"史上最强"半年报，CXO板块沸腾！医疗ETF（512170）覆盖的6只CXO龙头股集体上攻，药明康德涨7.72%，股价逼近100元，创3年新高！成 交90.14亿元，位列A股第7。此外，九洲药业涨停，昭衍新药午后触板。 中金公司指出，如今创新药板块估值中枢上修，预期BD资金和二级热度上涨将反哺国内新药研发需求起量以及一级创新药项目融资活跃度提升，内需CRO 有望受益。另一方面，中国企业成本与效率优势对海外客户具较强吸引力，外需CDMO订单趋势同样向好。 中泰证券提示，随着财报陆续披露，CXO、GLP-1等景气赛道表现亮眼。 ...